Diamond Hill Capital Management Inc. Sells 49,320 Shares of uniQure N.V. $QURE

Diamond Hill Capital Management Inc. decreased its position in uniQure N.V. (NASDAQ:QURE) by 59.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 33,333 shares of the biotechnology company’s stock after selling 49,320 shares during the period. Diamond Hill Capital Management Inc. owned about 0.06% of uniQure worth $1,946,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in QURE. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. Main Management ETF Advisors LLC lifted its position in uniQure by 1.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after buying an additional 912 shares in the last quarter. Ballentine Partners LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $301,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Stock Performance

NASDAQ QURE opened at $25.65 on Monday. The stock has a market cap of $1.60 billion, a PE ratio of -5.84 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a 50-day moving average of $23.44 and a 200-day moving average of $28.92. uniQure N.V. has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. On average, sell-side analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, Director Jack Kaye sold 6,390 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on QURE shares. Wells Fargo & Company dropped their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. The Goldman Sachs Group lowered their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Finally, HC Wainwright cut their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $58.33.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.